Connect Biopharma to Present at SVB Securities Global Biopharma Conference and Participate in BioCom CaliforniaGlobeNewsWire • 02/06/23
Connect Biopharma to Present at the San Francisco Biotech Showcase in JanuaryGlobeNewsWire • 12/19/22
CORRECTING and REPLACING -- Connect Biopharma Reports CBP-201 Achieved All Primary and Key Secondary Endpoints in Pivotal Atopic Dermatitis (AD) Trial in ChinaGlobeNewsWire • 10/04/22
Connect Biopharma Reports CBP-201 Achieved All Primary and Key Secondary Endpoints in Pivotal Atopic Dermatitis (AD) Trial in ChinaGlobeNewsWire • 10/04/22
Connect Biopharma to Host a Conference Call Tuesday, October 4 to Discuss Topline Results for the Pivotal Trial in China of Lead Candidate, CBP-201, in Patients with Moderate-to-Severe Atopic DermatitisGlobeNewsWire • 10/03/22
Connect Biopharma Reports First Half 2022 Financial Results and Provides Business UpdateGlobeNewsWire • 09/13/22
Connect Biopharma to Report First Half 2022 Financial Results on September 13GlobeNewsWire • 09/01/22
Connect BioPharma Successfully Completes CBP-174 Phase 1 Single Ascending Dose StudyGlobeNewsWire • 08/30/22
Connect Moves Forward CBP-201 Top-Line Results Timeline for Pivotal China Atopic Dermatitis Trial to Second Half 2022GlobeNewsWire • 07/11/22
All You Need to Know About Connect Biopharma Holdings Limited Sponsored ADR (CNTB) Rating Upgrade to BuyZacks Investment Research • 06/08/22
Connect Biopharma Presents CBP-201 Target Engagement and Immune Modulation Data at the Society for Investigative Dermatology Annual ConferenceGlobeNewsWire • 05/17/22
Connect Biopharma Stock Plunges As Ulcerative Colitis Candidate Flunks In Mid-Stage StudyBenzinga • 05/04/22
Connect Biopharma Announces Week 12 Top-Line Results from Phase 2 CBP-307 Trial in Patients with Moderate-to-Severe Ulcerative ColitisGlobeNewsWire • 05/03/22
Connect Biopharma Reports Full Year 2021 Financial Results and Provides Business UpdateGlobeNewsWire • 03/31/22
Connect Biopharma Appoints Autoimmune and Immunology Expert Chin Lee, MD, MPH as Chief Medical OfficerGlobeNewsWire • 03/01/22
Connect Biopharma to Participate at the SVB Leerink 11th Annual Global Healthcare ConferenceGlobeNewsWire • 02/09/22
Connect Biopharma Presents Data and Analyses from the Global Phase 2b Trial of CBP-201 at the Maui Derm ConferenceGlobeNewsWire • 01/24/22
Connect Biopharma Reports Detailed Positive Dataset from the Global Phase 2b Trial of CBP-201 in Adult Patients with Moderate-to-Severe Atopic DermatitisGlobeNewsWire • 01/05/22